King Pharmaceuticals KG AmTrust Reinsurance — Purchase significant reinsurance for losses above

Similar metrics at other companies

RGAAssets held in trust accounts, reinsurance agreements

$8.39B+57.5%

AIGReinsurance assets

$34.9B+2.2%

SPNTReinsurance — Catastrophe losses

$5.4M-91.4%

ORIAssets held in trust accounts, reinsurance agreements

$403M+7.8%

ORIReinsurance recoverable for loss and loss adjustment expense reserves

$6.5B+9.8%

SPNTReinsurance — Attritional losses

$145.7M-11.2%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept kg:ShortDurationInsuranceContractsMinimumLossesPurchased.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's amtrust reinsurance — purchase significant reinsurance for losses above.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's amtrust reinsurance — purchase significant reinsurance for losses above?: King Pharmaceuticals (KG) reported amtrust reinsurance — purchase significant reinsurance for losses above of $2.5M in Q4 2025.
What does amtrust reinsurance — purchase significant reinsurance for losses above mean?: Defines the attachment point or threshold at which the segment transfers risk to external reinsurers for large loss events. This metric is critical for assessing the segment's risk appetite and the effectiveness of its capital protection strategies.